ICPT Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conferences:

• Cowen 39th Annual Healthcare Conference at 8:00 a.m. ET on Tuesday, March 12, 2019
• Oppenheimer 29th Annual Healthcare Conference at 11:30 a.m. ET on Tuesday, March 19, 2019

Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.

About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

CONTACT

For more information about Intercept, please contact:

         Mark Vignola

         +1-646-747-1000

         investors@interceptpharma.com

         Media inquiries: media@interceptpharma.com